Ligand Pharmaceuticals Announces Fourth Quarter and Full Year 2025 Financial Results Call Scheduled for February 26, 2026
Ligand Pharmaceuticals (LGND) will release its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, followed by a conference call at 8:30 a.m. ET to discuss the results and provide a business update. The biopharmaceutical company focuses on supporting the development of medicines through financing and licensing technologies, partnering with leading pharmaceutical companies, and leveraging its Captisol® and NITRICIL™ platform technologies. The article also provides detailed information on insider trading activity, institutional holdings, analyst ratings, and price targets for LGND.
Impax Asset Management Group plc Sells 60,000 Shares of Ligand Pharmaceuticals Incorporated $LGND
Impax Asset Management Group plc has reduced its stake in Ligand Pharmaceuticals (NASDAQ:LGND) by 23.1%, selling 60,000 shares but still retaining over 200,000 shares valued at approximately $35.5 million. Analyst sentiment for LGND is positive, with a "Moderate Buy" consensus rating and a target price significantly above its current trading price. However, company insiders have been engaged in selling shares, indicating some internal divestment.
Villere ST Denis J & Co. LLC Has $49.59 Million Stock Position in Ligand Pharmaceuticals Incorporated $LGND
Villere ST Denis J & Co. LLC has reduced its stake in Ligand Pharmaceuticals Incorporated by 2.5%, now holding 279,950 shares valued at $49.59 million, representing 1.43% of the company. Despite this reduction, Ligand Pharmaceuticals remains Villere ST Denis J & Co. LLC's second-largest holding, accounting for 4.8% of its portfolio. The biotechnology company has received a "Moderate Buy" consensus rating from analysts, with an average price target of $239.33, and reported strong Q3 earnings with $3.09 EPS and 123% YoY revenue growth.
Stephens Investment Management Group LLC Sells 50,271 Shares of Ligand Pharmaceuticals Incorporated $LGND
Stephens Investment Management Group LLC reduced its stake in Ligand Pharmaceuticals (NASDAQ:LGND) by 8.3% in the third quarter, selling over 50,000 shares. Despite this, the firm still holds a significant position worth approximately $98.23 million. Ligand Pharmaceuticals reported strong earnings and revenue, with positive analyst sentiment, maintaining a "Moderate Buy" rating and a consensus price target indicating potential upside.
Ligand Pharmaceuticals Insiders Sell US$2.8m Of Stock, Possibly Signalling Caution
Over the past year, insiders at Ligand Pharmaceuticals (NASDAQ:LGND) sold US$2.8 million worth of stock, while purchasing US$1.2 million. This significant selling, particularly by Independent Director Jason Aryeh at a price below the current valuation and recent sales by CFO Octavio Espinoza, suggests a cautious outlook from insiders. Despite insiders holding 2.1% of the company, the net selling activities raise questions for potential investors.
Ligand Pharmaceuticals Incorporated $LGND Position Trimmed by Rice Hall James & Associates LLC
Rice Hall James & Associates LLC reduced its stake in Ligand Pharmaceuticals (NASDAQ:LGND) by 12.7% in Q3, now owning 294,490 shares valued at $52.17 million. Despite this trim, LGND remains its third-largest position, representing 2.8% of its investment portfolio. Ligand Pharmaceuticals reported strong earnings with an EPS of $3.09 and revenue of $86.89 million for the quarter, exceeding analyst expectations.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Recommendation of "Moderate Buy" by Analysts
Ligand Pharmaceuticals (NASDAQ:LGND) has received a "Moderate Buy" consensus rating from analysts, with an average 1-year price target of approximately $239.33, following several raised price objectives. The company reported strong quarterly earnings, beating expectations with an EPS of $3.09 and revenue up 123% year-over-year, and has set optimistic FY2025 guidance. Insider activity shows recent stock sales by the CFO and a director, while institutional investors hold a significant majority of the shares.
Analysts’ Top Healthcare Picks: Ligand Pharma (LGND), MiMedx Group (MDXG)
This article highlights bullish sentiments from financial analysts on several healthcare stocks. Ligand Pharma (LGND) received a Strong Buy rating with a significant upside, supported by analysts from Craig-Hallum and Citi. MiMedx Group (MDXG) also earned a Strong Buy consensus, with a substantial potential upside, and was reaffirmed by Craig-Hallum.
Ligand Pharmaceuticals Stock (LGND) Opinions on 2025 Investor Day and 2026 Guidance
Ligand Pharmaceuticals' 2025 Investor Day in New York City generated discussion on X regarding its updated 2026 revenue guidance, projected between $245 million and $285 million, with a focus on royalty portfolio growth and strategic partnerships. The stock has seen a 57.96% increase over the past year, trading at $195.56, though some investors remain cautious. Insider trading shows 29 sales in the past 6 months, and institutional investors have largely increased their positions.
Ligand Pharmaceuticals Stock (LGND) Opinions on 2025 Investor Day and 2026 Guidance
Ligand Pharmaceuticals (LGND) held its 2025 Investor Day, sparking discussions on X about its updated 2026 revenue guidance of $245 million to $285 million and focus on royalty portfolio growth. The stock saw a slight uptick to $195.56, reflecting mixed investor sentiment. Insider trading activity shows 29 sales and no purchases in the last six months, while institutional investors have largely increased their positions.
Ligand Pharmaceuticals Provides 2026 Revenue Guidance of $245 Million to $285 Million with Increased Royalty Revenue Outlook | LGND Stock News
Ligand Pharmaceuticals announced its 2026 revenue guidance, projecting between $245 million and $285 million, a 15% increase in core revenue growth. Royalty revenues are expected to rise 40% to $200-$225 million, driven by key products and supported by $1 billion in deployable capital. The company also anticipates core adjusted earnings per diluted share between $8.00 and $9.00 and foresees a long-term compound annual growth rate of at least 23% in royalty receipts.
Ligand Pharmaceuticals Incorporated $LGND Shares Bought by Legal & General Group Plc
Legal & General Group Plc increased its stake in Ligand Pharmaceuticals (NASDAQ:LGND) by 15.8% in Q2, acquiring 16,171 additional shares. This brings their total holding to 118,333 shares, valued at approximately $13.45 million. The biotechnology company reported strong quarterly earnings, beating analyst expectations, and has received multiple price target increases from brokerage firms.
Peering Into Ligand Pharmaceuticals Inc's Recent Short Interest
Ligand Pharmaceuticals Inc. (LGND) has seen a 7.23% decrease in its short interest, with 1.11 million shares now sold short, representing 6.8% of available shares. This decline in short interest suggests a potentially more bullish sentiment among investors for the company. Compared to its peers, Ligand Pharmaceuticals Inc. has less short interest on average.
Ligand (NASDAQ: LGND) to join UBS, Stifel, IDEAS conferences; fireside chat Nov 12
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that CEO Todd Davis and CFO Tavo Espinoza will participate in three investor conferences in November 2025. These include one-on-one meetings at the UBS Global Healthcare Conference on November 10, a fireside chat at the Stifel 2025 Healthcare Conference on November 12, and a presentation at the Southwest IDEAS 2025 Investor Conference on November 20. Investors interested in scheduling one-on-one meetings should contact their UBS or Stifel representatives.
Ligand Pharmaceuticals stock hits 52-week high at 186.46 USD By Investing.com - Investing.com UK
Ligand Pharmaceuticals stock reached a new 52-week high, trading at 186.46 USD. This achievement reflects a significant milestone for the company's market performance.
Ligand Pharmaceuticals Incorporated $LGND Shares Bought by Maryland State Retirement & Pension System - Defense World
Maryland State Retirement & Pension System has increased its stake in Ligand Pharmaceuticals Inc. Other institutional investors such as Maseco LLP, Opal Wealth Advisors LLC, GAMMA Investing LLC, Mirae Asset Global Investments Co. Ltd., and Exchange Traded Concepts LLC also made changes to their holdings. Analysts from Royal Bank Of Canada have raised their price target for Ligand Pharmaceuticals shares.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Rating of “Moderate Buy” by Analysts
Ligand Pharmaceuticals (NASDAQ:LGND) has received a "Moderate Buy" consensus rating from analysts, with several firms increasing their price targets and issuing "buy" or "outperform" ratings. The article also details recent insider stock sales and significant institutional investor activity, including new stakes and increased holdings in the company. Ligand Pharmaceuticals is a biopharmaceutical company focused on developing and licensing biopharmaceutical assets globally.
Ligand Pharmaceuticals (LGND): Evaluating Valuation After FDA Green Light for Lasix ONYU’s At-Home Heart Failure Solution
Ligand Pharmaceuticals (LGND) has received FDA approval for Lasix ONYU, a drug-device product for chronic heart failure, leading to significant share price appreciation. The article evaluates LGND's valuation, presenting a narrative that suggests the stock is 2.9% undervalued with a fair value of $183.12, reflecting high market conviction in its future earnings and margin expansion. However, a contrasting view highlights a high price-to-sales ratio of 18.6x compared to the industry average of 4.7x, indicating potential valuation risk if growth falters.
Ligand Pharmaceuticals Announces FDA Approval of Lasix ONYU, Innovative Subcutaneous Delivery Device for Edema Treatment in Heart Failure Patients | LGND Stock News
Ligand Pharmaceuticals announced FDA approval for Lasix ONYU, a novel subcutaneous delivery device for furosemide, targeting edema in chronic heart failure patients. This innovative system, which uses Ligand's Captisol technology, allows for at-home treatment, offering a cost-effective alternative to hospital-administered IV diuretics. Lasix ONYU is expected to be available by late 2025 and aims to reduce hospitalizations for the millions affected by heart failure.
Ligand Pharmaceuticals Prices $400 Million Convertible Senior Notes Due 2030
Ligand Pharmaceuticals has priced $400 million in 0.75% convertible senior notes due 2030 in a private placement, with an option for initial purchasers to buy an additional $60 million. The company plans to use the net proceeds for convertible note hedge transactions, share repurchases, and general corporate purposes. This financial move aims to enhance flexibility, but also carries potential risks such as investor dilution and market volatility from hedging activities.
Ligand Pharmaceuticals Partner Pelthos Therapeutics Launches ZELSUVMI™ for Molluscum Contagiosum Treatment
Ligand Pharmaceuticals' partner Pelthos Therapeutics has launched ZELSUVMI™ (berdazimer) topical gel 10.3%, the first FDA-approved at-home treatment for molluscum contagiosum. This launch triggers a $5 million milestone payment to Ligand and establishes a 13% royalty on worldwide sales for the company. Ligand also now holds a 56% ownership stake in Pelthos Therapeutics, strengthening its position in this innovative treatment for a widespread viral skin condition.
Ligand Forms $50M Dermatology Powerhouse: First Home-Use Molluscum Treatment Coming
Ligand Pharmaceuticals has completed a merger between its subsidiary LNHC, Inc. and Channel Therapeutics' CHRO Merger Sub Inc., forming Pelthos Therapeutics. The new entity, trading as "PTHS" on NYSE American starting July 2, 2025, raised $50.1 million in equity capital. Pelthos will launch ZELSUVMI™, the first home-administered prescription treatment for Molluscum contagiosum infections, in July 2025, and Ligand will receive a 13% royalty on worldwide sales.
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics
Ligand Pharmaceuticals' subsidiary Pelthos Therapeutics will combine with Channel Therapeutics in a merger supported by $50 million in equity capital. The combined company, operating as Pelthos Therapeutics Inc. (ticker PTHS), will focus on commercializing ZELSUVMI™, an FDA-approved treatment for Molluscum contagiosum, and continue Channel's NaV 1.7 pain treatment programs. Ligand will retain a 13% royalty on worldwide sales of ZELSUVMI.
Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Share Price Matching Investor Opinion
Ligand Pharmaceuticals (NASDAQ:LGND) currently trades at a high P/E ratio of 48.9x, significantly above the U.S. market average. This premium valuation is attributed to the company's strong historical earnings growth of 105% last year, and particularly its robust future earnings outlook, with analysts forecasting 24% annual growth over the next three years, compared to an 11% market average. Investors are seemingly comfortable with the high P/E, expecting this superior growth to continue, thus suggesting the share price reflects positive investor sentiment regarding future earnings.
Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences
Ligand Pharmaceuticals has finalized a $75 million royalty financing agreement with Castle Creek Biosciences to fund the Phase 3 clinical trial of D-Fi (FCX-007), a gene therapy for dystrophic epidermolysis bullosa (DEB). Ligand invested $50 million and led a syndicate including Paragon Biosciences, Valor Equity Partners, and XOMA Royalty Corporation, which contributed an additional $25 million, in exchange for a high-single digit royalty on D-Fi's worldwide sales. D-Fi is an injectable autologous gene-modified cell therapy aimed at treating the rare genetic skin disorder DEB, and has received multiple FDA designations, including Orphan Drug and Fast Track.
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
Ligand Pharmaceuticals launched Pelthos Therapeutics, a new biopharmaceutical company, to commercialize ZELSUVMI™ (berdazimer) topical gel, 10.3%, for molluscum contagiosum. Scott Plesha was appointed CEO of Pelthos, and ZELSUVMI, the first FDA-approved at-home topical treatment for molluscum, is expected to be available in late 2024. This move is part of Ligand's strategy to maximize the value of differentiated pharmaceutical assets by creating new entities with independent management and funding.
LGND: 2025 View Calls for 17% Topline Growth
Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) held its annual analyst day on December 10, 2024, forecasting 2025 revenues between $180 to $200 million, representing a 17% increase, and core adjusted EPS of $6.00 to $6.25. This growth is anticipated to be driven by strong royalty revenues from products like Filspari, Qarziba, Ohtuvayre, and Capvaxive, as well as increased Captisol sales to Gilead. The company detailed its investment strategy, financial capacity, and provided an updated valuation, setting a target price of $141 per share.
Ligand: Buy This Pharma And Get A Stake In Dozens Of Therapies (NASDAQ:LGND)
Ligand Pharmaceuticals (LGND) receives a "Buy" rating due to its strong liquidity, clean balance sheet, and robust Q3 2024 earnings performance, which beat expectations and raised prior guidance. The company's consistent financial performance and solid position make it an attractive investment choice. This article is the author's eighth on Ligand, noting a modest ~9.6% increase since the previous "Buy" recommendation in July 2024.
Ligand taps Apeiron for a new royalty stream | ApexOnco - Clinical Trials news and analysis
Ligand Pharmaceuticals has acquired Apeiron for an upfront fee of $100 million, primarily to secure royalty streams from Apeiron's sole approved product, Qarziba, marketed in the EU for neuroblastoma. Ligand will also invest up to $4 million in inVIOs, Apeiron's spin-off for novel, higher-risk projects. This move aligns with Ligand's strategy of combining relatively safe bets with longer-shot investments in its oncology royalty portfolio, capitalized on companies seeking financing in the current market.
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI
Ligand Pharmaceuticals has launched Pelthos Therapeutics, a new biopharmaceutical company, to commercialize ZELSUVMI™ (berdazimer) topical gel for molluscum contagiosum. Scott Plesha has been appointed CEO of Pelthos, bringing over 30 years of industry experience. ZELSUVMI, the first FDA-approved at-home topical treatment for molluscum, is expected to be available in late 2024, with Ligand planning to commercialize it in partnership with a capital provider or strategic partner.
Watkins Advises Ligand Pharmaceuticals and OmniAb in Completion of Spin-Off and Business Combination
Latham & Watkins LLP advised Ligand Pharmaceuticals and OmniAb in the completion of a tax-free distribution and subsequent business combination. This transaction resulted in OmniAb, Inc. becoming an independent publicly traded company on Nasdaq under the ticker symbol “OABI.” The deal is notable as one of the first Reverse Morris Trust transactions combined with a deSPAC.
Avista Public Acquisition Corp. II (AHPA) Shareholders Approve Ligand Deal
Avista Public Acquisition Corp. II (AHPA) shareholders have approved the combination with Ligand Pharmaceuticals Incorporated to spin off its antibody discovery business, OmniAb, Inc. The deal was overwhelmingly approved despite a high 94.41% redemption rate, leaving OmniAb with approximately $95 million in net cash. The spin-off is on track to close on November 1st, with Ligand shareholders set to receive shares of OmniAb common stock.
Ligand ‘Anchored Spin-Off’ Is SPAC Variation on Sponsored Spin
This article discusses Ligand Pharmaceuticals' proposed spin-off of its OmniAb antibody discovery business, followed by a merger with Avista Public Acquisition Corp. II (APAC), a SPAC. The authors describe this "anchored spin-off" as a hybrid of a sponsored spin and a Reverse Morris Trust, offering benefits like establishing Spinco's value and securing an anchor investor. The transaction is designed to be tax-free for Ligand and its shareholders, with Avista Capital Partners investing additional cash into the post-merger company.
Ligand takes a crack at a SPAC to buoy spun-off antibody discovery business
Ligand Pharmaceuticals is spinning off its antibody discovery unit, OmniAB, and taking it public through a SPAC merger with Avista Public Acquisition Corp. The deal values OmniAB at $850 million pre-money and comes a month after Ligand's initial plans to break out the unit. Despite a decline in the general appetite for SPACs, OmniAB brings significant experience with partnerships and programs in development.
) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy
Ligand Pharmaceuticals announced that its partner CStone Pharmaceuticals received approval from China's NMPA for sugemalimab (Cejemly®) for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy. Sugemalimab, an OmniAb-derived anti-PD-L1 monoclonal antibody, demonstrated significant improvement in progression-free survival in Phase 3 studies. This approval marks another significant milestone for OmniAb-derived medicines, highlighting the platform's potential in oncology.
GenScript Biotech and Ligand Pharmaceuticals Enter into Global OmniAb® Licensing Agreement
GenScript Biotech Corporation and Ligand Pharmaceuticals Incorporated announced a strategic licensing agreement for Ligand's OmniAb® Platform, enabling GenScript to expand its fully human antibody discovery services globally. This agreement makes GenScript ProBio the second CDMO in China to secure a global license for the OmniAb platform's transgenic rodent technology, accelerating the development of therapeutic antibodies. The partnership aims to provide customers with rapid, high-quality antibody discovery leveraging industry-leading technology.
Ligand Buys Pfenex in $516 Million Deal to Access Protein Production Platform
Ligand Pharmaceuticals is acquiring Pfenex for a total deal transaction of up to $516 million, gaining access to Pfenex's proprietary protein production platform. The deal, expected to close in the fourth quarter, includes $438 million in equity value and a potential $78 million as a Contingent Value Right. This acquisition will expand Ligand's licensing and royalty revenue streams and enhance its position in developing therapeutics.
Ligand to Acquire Pfenex Inc.
Ligand Pharmaceuticals has announced a definitive agreement to acquire Pfenex Inc. for $12.00 per share in cash, totaling $438 million in equity value. An additional $2.00 per share ($78 million) will be paid as a Contingent Value Right if a regulatory milestone is met by December 31, 2021, bringing the total transaction value to up to $516 million. The acquisition aims to expand Ligand's technology offerings with Pfenex's proprietary protein expression platform and is expected to be earnings accretive in 2021.
Vireo Health teams with Ligand on cannabis delivery methods
Vireo Health, a multistate marijuana company, has partnered with Ligand Pharmaceuticals, a well-established drug developer, to explore new cannabis delivery methods. This collaboration focuses on using Ligand's Captisol to improve the solubility, stability, and bioavailability of cannabinoid-based medicines. The goal is to develop FDA-approved cannabis products, potentially including intravenous applications to replace traditional pain relief like morphine in emergency settings.
Explainer: What is Ligandrol and how does it work?
This article explains Ligandrol, a selective androgen receptor modulator (SARM), discussing its history, how it works to build muscle, and why it is banned in professional sports. It highlights the drug's experimental status, its potential medical applications, and the risks associated with contaminated supplements.
Ligand and SQ Innovation Enter into Exclusive Worldwide Captisol® License and Supply Agreements for High-Concentration Furosemide Formulation
Ligand Pharmaceuticals and SQ Innovation have announced exclusive worldwide Captisol® license and supply agreements for a high-concentration furosemide formulation. This collaboration aims to develop a cost-effective subcutaneous diuretic treatment for heart failure patients, leveraging Ligand's Captisol technology to enable a smaller delivery volume. The new formulation, planned for use with advanced drug delivery platforms, is intended to reduce hospitalizations and healthcare costs associated with fluid overload in heart failure.
2019 Distinguished Faculty Award - Donald McDonnell, PhD
Donald McDonnell, PhD, was honored with Duke Medical Alumni Association's 2019 Distinguished Faculty Award for his pioneering work in nuclear hormone receptors and drug discovery, particularly in breast cancer treatment. His research includes developing new therapies for ER-positive breast cancer and identifying links between obesity, cholesterol, and breast cancer risk. McDonnell is also recognized for his significant contributions as a mentor, educator, and administrator at Duke University.
Captisol®: an efficient carrier and solubilizing agent for essential oils and their components
This study evaluates Captisol® and Captisol-G® as carriers and solubilizing agents for essential oils (EOs) and their components, comparing their performance to HP-β-CD and γ-CD. The research demonstrates that Captisol® shows superior binding ability, effectively increasing the aqueous solubility of EOs and enabling controlled release systems. These findings suggest Captisol® is a promising candidate for formulating EOs in pharmaceutical applications due to its efficient encapsulation and solubilization properties.
SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm
Lundin Law PC has announced a class action lawsuit against Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) on behalf of investors who purchased shares between November 9, 2015, and November 14, 2016. The lawsuit alleges that Ligand made false and misleading statements, including overstating deferred tax assets, misclassifying debt, and lacking effective internal controls over financial reporting. Investors are encouraged to contact the firm before the January 17, 2017 lead plaintiff motion deadline.
Ligand Pharma Inks Captisol Supply Agreement With Merck - Quick Facts
Ligand Pharmaceuticals Inc. announced a Captisol supply agreement with Merck & Co., Inc. for an undisclosed program. Ligand will provide clinical and commercial supplies of Captisol, a patented cyclodextrin designed to optimize drug solubility and stability, with potential annual delivery of multiple metric tons if the program is commercialized. The financial terms of the deal were not disclosed, but Ligand expressed satisfaction with the long-term commercial partnership.
